Cpi-613 inhibitor – A lipoic acid derivative different from standard cytotoxic chemotherapy, devimistat is currently being studied in combination with modified FOLFIRINOX to treat various solid tumors and heme malignancies.
Description
Cpi-613 is being studied for the treatment of patients with metastatic pancreatic cancer
Server
cloudflare
DNS
View domain name system records, including the A, AAAA, MX and NS records.